Literature DB >> 34481764

Tilting MYC toward cancer cell death.

Colleen T Harrington1, Elena Sotillo2, Chi V Dang3, Andrei Thomas-Tikhonenko4.   

Abstract

MYC oncoprotein promotes cell proliferation and serves as the key driver in many human cancers; therefore, considerable effort has been expended to develop reliable pharmacological methods to suppress its expression or function. Despite impressive progress, MYC-targeting drugs have not reached the clinic. Recent advances suggest that within a limited expression range unique to each tumor, MYC oncoprotein can have a paradoxical, proapoptotic function. Here we introduce a counterintuitive idea that modestly and transiently elevating MYC levels could aid chemotherapy-induced apoptosis and thus benefit the patients as much, if not more than MYC inhibition.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MYC; apoptosis, chemotherapy; oncogene addiction

Mesh:

Substances:

Year:  2021        PMID: 34481764      PMCID: PMC8541926          DOI: 10.1016/j.trecan.2021.08.002

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  148 in total

Review 1.  EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.

Authors:  I K Ruf; P W Rhyne; H Yang; C M Borza; L M Hutt-Fletcher; J L Cleveland; J T Sample
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

Review 2.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

3.  Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Authors:  Kristopher A Sarosiek; Cameron Fraser; Nathiya Muthalagu; Patrick D Bhola; Weiting Chang; Samuel K McBrayer; Adam Cantlon; Sudeshna Fisch; Gail Golomb-Mello; Jeremy A Ryan; Jing Deng; Brian Jian; Chris Corbett; Marti Goldenberg; Joseph R Madsen; Ronglih Liao; Dominic Walsh; John Sedivy; Daniel J Murphy; Daniel Ruben Carrasco; Shenandoah Robinson; Javid Moslehi; Anthony Letai
Journal:  Cancer Cell       Date:  2016-12-22       Impact factor: 31.743

4.  Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Authors:  Colleen T Harrington; Elena Sotillo; Aude Robert; Katharina E Hayer; Agata M Bogusz; James Psathas; Duonan Yu; Deanne Taylor; Chi V Dang; Peter S Klein; Michael D Hogarty; Birgit Geoerger; Wafik S El-Deiry; Joëlle Wiels; Andrei Thomas-Tikhonenko
Journal:  Leukemia       Date:  2019-03-26       Impact factor: 11.528

5.  Drugging MYCN through an allosteric transition in Aurora kinase A.

Authors:  William Clay Gustafson; Justin Gabriel Meyerowitz; Erin A Nekritz; Justin Chen; Cyril Benes; Elise Charron; Erin F Simonds; Robert Seeger; Katherine K Matthay; Nicholas T Hertz; Martin Eilers; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2014-08-28       Impact factor: 31.743

6.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

Authors:  Tobias Otto; Sebastian Horn; Markus Brockmann; Ursula Eilers; Lars Schüttrumpf; Nikita Popov; Anna Marie Kenney; Johannes H Schulte; Roderick Beijersbergen; Holger Christiansen; Bernd Berwanger; Martin Eilers
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

7.  E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Authors:  Sara Ladu; Diego F Calvisi; Elizabeth A Conner; Miriam Farina; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2008-07-17       Impact factor: 22.682

8.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

Authors:  F Zindy; C M Eischen; D H Randle; T Kamijo; J L Cleveland; C J Sherr; M F Roussel
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

9.  Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Authors:  Brittany L Allen-Petersen; Tyler Risom; Zipei Feng; Zhiping Wang; Zina P Jenny; Mary C Thoma; Katherine R Pelz; Jennifer P Morton; Owen J Sansom; Charles D Lopez; Brett Sheppard; Dale J Christensen; Michael Ohlmeyer; Goutham Narla; Rosalie C Sears
Journal:  Cancer Res       Date:  2018-11-02       Impact factor: 13.312

Review 10.  Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors.

Authors:  Mihai I Truica; Michael C Burns; Huiying Han; Sarki A Abdulkadir
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

View more
  3 in total

1.  The identification and validation of hub genes associated with advanced IPF by weighted gene co-expression network analysis.

Authors:  Lingyi Liu; Yanru Yang; Xin Han; Jiwei Hou
Journal:  Funct Integr Genomics       Date:  2022-09-15       Impact factor: 3.674

2.  Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.

Authors:  Chang-Tsu Yuan; Shih-Sung Chuang; Pei-Yuan Cheng; Koping Chang; Hsuan Wang; Jia-Huei Tsai; Jau-Yu Liau; Wen-Chien Chou
Journal:  J Pathol Clin Res       Date:  2022-06-17

3.  Stabilization of the c-Myc Protein via the Modulation of Threonine 58 and Serine 62 Phosphorylation by the Disulfiram/Copper Complex in Oral Cancer Cells.

Authors:  Gunng-Shinng Chen; Ssu-Yu Chen; Shu-Ting Liu; Cheng-Chih Hsieh; Shiao-Pieng Lee; Shih-Ming Huang
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.